The prognostic value of hemoglobin change after initiating androgen-deprivation therapy for newly diagnosed metastatic prostate cancer: A multivariate analysis of southwest oncology group study 8894

Tomasz (Tom) Beer, Catherine M. Tangen, Lisa B. Bland, Maha Hussain, Bryan H. Goldman, Thomas Deloughery, E. David Crawford

    Research output: Contribution to journalArticle

    22 Citations (Scopus)

    Abstract

    BACKGROUND. The objective of this study was to characterize changes in hemoglobin (HGB) levels after the initiation of androgen-deprivation therapy (ADT) in patients with previously untreated, metastatic prostate cancer who were enrolled in a large clinical trial. METHODS. The multivariate associations between 3-month change in HGB and baseline characteristics were evaluated with a linear regression model. The associations between 3-month change in HGB level and time-to-event outcomes, including overall survival and progression-free survival, were evaluated by using proportional hazards regression models. RESULTS. Quartiles of baseline HGB levels were ≤12.0 g/dL, from 12.1 to 13.7 g/dL, from 13.8 to 14.7 g/dL, and >14.7 g/dL. Overall, 3 months after initiating ADT, the mean HGB level declined 0.54 g/dL (standard deviation [SD], 1.68 g/dL); however, the mean HGB level increased by 0.99 g/dL (SD, 1.83 g/dL) in patients who had baseline HGB levels

    Original languageEnglish (US)
    Pages (from-to)489-496
    Number of pages8
    JournalCancer
    Volume107
    Issue number3
    DOIs
    StatePublished - Aug 1 2006

    Fingerprint

    Androgens
    Prostatic Neoplasms
    Hemoglobins
    Multivariate Analysis
    Therapeutics
    Linear Models
    Proportional Hazards Models
    Disease-Free Survival
    Clinical Trials
    Survival

    Keywords

    • Androgen-deprivation
    • Anemia
    • Prognosis
    • Prostate cancer
    • Therapy

    ASJC Scopus subject areas

    • Cancer Research
    • Oncology

    Cite this

    The prognostic value of hemoglobin change after initiating androgen-deprivation therapy for newly diagnosed metastatic prostate cancer : A multivariate analysis of southwest oncology group study 8894. / Beer, Tomasz (Tom); Tangen, Catherine M.; Bland, Lisa B.; Hussain, Maha; Goldman, Bryan H.; Deloughery, Thomas; Crawford, E. David.

    In: Cancer, Vol. 107, No. 3, 01.08.2006, p. 489-496.

    Research output: Contribution to journalArticle

    @article{5d822657225644ef94051ddd5288fc59,
    title = "The prognostic value of hemoglobin change after initiating androgen-deprivation therapy for newly diagnosed metastatic prostate cancer: A multivariate analysis of southwest oncology group study 8894",
    abstract = "BACKGROUND. The objective of this study was to characterize changes in hemoglobin (HGB) levels after the initiation of androgen-deprivation therapy (ADT) in patients with previously untreated, metastatic prostate cancer who were enrolled in a large clinical trial. METHODS. The multivariate associations between 3-month change in HGB and baseline characteristics were evaluated with a linear regression model. The associations between 3-month change in HGB level and time-to-event outcomes, including overall survival and progression-free survival, were evaluated by using proportional hazards regression models. RESULTS. Quartiles of baseline HGB levels were ≤12.0 g/dL, from 12.1 to 13.7 g/dL, from 13.8 to 14.7 g/dL, and >14.7 g/dL. Overall, 3 months after initiating ADT, the mean HGB level declined 0.54 g/dL (standard deviation [SD], 1.68 g/dL); however, the mean HGB level increased by 0.99 g/dL (SD, 1.83 g/dL) in patients who had baseline HGB levels",
    keywords = "Androgen-deprivation, Anemia, Prognosis, Prostate cancer, Therapy",
    author = "Beer, {Tomasz (Tom)} and Tangen, {Catherine M.} and Bland, {Lisa B.} and Maha Hussain and Goldman, {Bryan H.} and Thomas Deloughery and Crawford, {E. David}",
    year = "2006",
    month = "8",
    day = "1",
    doi = "10.1002/cncr.22029",
    language = "English (US)",
    volume = "107",
    pages = "489--496",
    journal = "Cancer",
    issn = "0008-543X",
    publisher = "John Wiley and Sons Inc.",
    number = "3",

    }

    TY - JOUR

    T1 - The prognostic value of hemoglobin change after initiating androgen-deprivation therapy for newly diagnosed metastatic prostate cancer

    T2 - A multivariate analysis of southwest oncology group study 8894

    AU - Beer, Tomasz (Tom)

    AU - Tangen, Catherine M.

    AU - Bland, Lisa B.

    AU - Hussain, Maha

    AU - Goldman, Bryan H.

    AU - Deloughery, Thomas

    AU - Crawford, E. David

    PY - 2006/8/1

    Y1 - 2006/8/1

    N2 - BACKGROUND. The objective of this study was to characterize changes in hemoglobin (HGB) levels after the initiation of androgen-deprivation therapy (ADT) in patients with previously untreated, metastatic prostate cancer who were enrolled in a large clinical trial. METHODS. The multivariate associations between 3-month change in HGB and baseline characteristics were evaluated with a linear regression model. The associations between 3-month change in HGB level and time-to-event outcomes, including overall survival and progression-free survival, were evaluated by using proportional hazards regression models. RESULTS. Quartiles of baseline HGB levels were ≤12.0 g/dL, from 12.1 to 13.7 g/dL, from 13.8 to 14.7 g/dL, and >14.7 g/dL. Overall, 3 months after initiating ADT, the mean HGB level declined 0.54 g/dL (standard deviation [SD], 1.68 g/dL); however, the mean HGB level increased by 0.99 g/dL (SD, 1.83 g/dL) in patients who had baseline HGB levels

    AB - BACKGROUND. The objective of this study was to characterize changes in hemoglobin (HGB) levels after the initiation of androgen-deprivation therapy (ADT) in patients with previously untreated, metastatic prostate cancer who were enrolled in a large clinical trial. METHODS. The multivariate associations between 3-month change in HGB and baseline characteristics were evaluated with a linear regression model. The associations between 3-month change in HGB level and time-to-event outcomes, including overall survival and progression-free survival, were evaluated by using proportional hazards regression models. RESULTS. Quartiles of baseline HGB levels were ≤12.0 g/dL, from 12.1 to 13.7 g/dL, from 13.8 to 14.7 g/dL, and >14.7 g/dL. Overall, 3 months after initiating ADT, the mean HGB level declined 0.54 g/dL (standard deviation [SD], 1.68 g/dL); however, the mean HGB level increased by 0.99 g/dL (SD, 1.83 g/dL) in patients who had baseline HGB levels

    KW - Androgen-deprivation

    KW - Anemia

    KW - Prognosis

    KW - Prostate cancer

    KW - Therapy

    UR - http://www.scopus.com/inward/record.url?scp=33746322319&partnerID=8YFLogxK

    UR - http://www.scopus.com/inward/citedby.url?scp=33746322319&partnerID=8YFLogxK

    U2 - 10.1002/cncr.22029

    DO - 10.1002/cncr.22029

    M3 - Article

    C2 - 16804926

    AN - SCOPUS:33746322319

    VL - 107

    SP - 489

    EP - 496

    JO - Cancer

    JF - Cancer

    SN - 0008-543X

    IS - 3

    ER -